• • Links
• • References

References

Publications Arising from Research Conducted at MDL

Glueck CJ, Haque M, Fontaine RN, Wang P. Stromelysin-1 5A/6A and
eNOS polymorphisms, MTHFR C677T-A1298C compound heterozygosity,
and cigarette-cannabis smoking: Gene-environment pathophysiological
associations with Buerger's disease. Submitted Jan 2005.

Patnaik M, Dlott JS, Fontaine RN, Subbiah MT, Hessner MJ, Joyner KA,
Ledford MR, Lau EC, Moehlenkamp C, Amos J, Zhang B, Williams TM.
Detection of genomic polymorphisms associated with venous thrombosis
using the invader biplex assay. J Mol Diagn. 2004 May;6(2):137-44.

Morrison JA, Gruppo R, Glueck CJ, Stroop D, Fontaine RN, Wang P,
Smith KL. Population-specific alleles: the polymorphism (K121Q) of the
human glycoprotein PC-1 gene is strongly associated with race but not with
insulin resistance in black and white children. Metabolism. 2004 Apr;53 (4):
465-8.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. Estrogen
replacement therapy, thrombophilia, and atherothrombosis. Metabolism.
2002 Jun; 51(6):724-32.

Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A,
Jauch E, Moomaw CJ, Shukla R, Gebel J, Fontaine R, Broderick J.
Subarachnoid hemorrhage: a preventable disease with a heritable
component. Stroke. 2002 May;33(5):1321-6.

Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J,
Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA,
Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk
factors for intracerebral hemorrhage: preliminary results of a population-
based study. Stroke. 2002 May;33(5):1190-5.

Glueck CJ, Freiberg RA, Fontaine RN, Sieve-Smith L, Wang P.
Anticoagulant therapy for osteonecrosis associated with heritable
hypofibrinolysis and thrombophilia. Expert Opin Investig Drugs. 2001 Jul;
10(7):1309-16. Review.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to
restore normal menses in oligo-amenorrheic teenage girls with polycystic
ovary syndrome (PCOS). J Adolesc Health. 2001 Sep;29(3):160-9.

Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher
P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P. Metformin reduces
weight, centripetal obesity, insulin, leptin, and low-density lipoprotein
cholesterol in nondiabetic, morbidly obese subjects with body mass index
greater than 30. Metabolism. 2001 Jul;50(7):856-61.

Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis,
thrombophilia, osteonecrosis. Clin Orthop. 2001 May;(386):19-33.

Glueck, C.J., R.N. Fontaine and P. Wang. Interaction of heritable and
estrogen-induced thrombophilia: possible pathoetiologies for ischemic optic
neuropathy and ischemic stroke. Thromb. Haemost. 2001 85:256-9.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. Interaction of
estrogen replacement therapy with the thrombophilic 20210 G/A
prothrombin gene mutation for atherothrombotic vascular disease: a cross-
sectional study of 275 hyperlipidemic women. Metabolism. 2001 Mar;50(3):
360-5.

Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A.
Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol. 2001
Jan;97(1):44-8.

Glueck CJ, Awadalla SG, Phillips H, Cameron D, Wang P, Fontaine RN.
Polycystic ovary syndrome, infertility, familial thrombophilia, familial
hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and
miscarriage. Fertil Steril. 2000 Aug;74(2):394-7.

Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, Sieve-
Smith L, Tracy T. The 4G/4G polymorphism of the hypofibrinolytic
plasminogen activator inhibitor type 1 gene: an independent risk factor for
serious pregnancy complications. Metabolism. 2000 Jul;49(7):845-52.

Glueck CJ, Fontaine RN, Gruppo R, Stroop D, Sieve-Smith L, Tracy T,
Wang P. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and
osteonecrosis. Clin Orthop. 1999 Sep;(366):133-46.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK.
Plasminogen activator inhibitor activity: an independent risk factor for the
high miscarriage rate during pregnancy in women with polycystic ovary
syndrome. Metabolism. 1999 Dec;48(12):1589-95.

Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. Effect
of exogenous estrogen on atherothrombotic vascular disease risk related to
the presence or absence of the factor V Leiden mutation (resistance to
activated protein C). Am J Cardiol. 1999 Sep 1;84(5):549-54.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-
induced resumption of normal menses in 39 of 43 (91%) previously
amenorrheic women with the polycystic ovary syndrome. Metabolism.
1999 Apr;48(4):511-9.

Glueck CJ, Bell H, Vadlamani L, Gupta A, Fontaine RN, Wang P, Stroop D,
Gruppo R. Heritable thrombophilia and hypofibrinolysis. Possible causes of
retinal vein occlusion. Arch Ophthalmol. 1999 Jan;117(1):43-9.

Glueck CJ, Fontaine RN, Gupta A, Alasmi M. Myocardial infarction in a 35-
year-old man with homocysteinemia, high plasminogen activator inhibitor
activity, and resistance to activated protein C. Metabolism. 1997 Dec;46(12):
1470-2.

Glueck CJ, Kelley W, Gupta A, Fontaine RN, Wang P, Gartside PS.
Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of
772 firefighters and cross-sectional evaluation of hypocholesterolemia in
1,479 men in the National Health and Nutrition Examination Survey I.
Metabolism. 1997 Jun;46(6):625-33.

Glueck, C.J., H. Phillips, D. Cameron, M. Meyers, R.N. Fontaine and P.
Wang. Estrogen replacement in a patient with familial protein S deficiency
associated with diarrhea, hyperglucagonemia, and osteonecrosis. Am. J.
Gastroenterology, In Review.

Glueck, C.J., R.A. Freiberg, R.N. Fontaine, T. Tracy and P. Wang
Hypofibrinolysis and thrombophilia in 36 patients referred for low molecular
weight heparin therapy for osteonecrosis of the hip. Clin. Orthop. In
Review

Glueck, C.J., Szczybutowicz, P. Wang and R.N. Fontaine. Three-
generation familial osteonecrosis, familial thrombophilia, and
hypofibrinolysis. Clin. Orthop., In Review.

Presentations:

Haque, MCJ Glueck, RN Fontaine, P Wang. Stromelysin-1 5A/6A AND
eNOS T-786C Polymorphism, MTHFR C677T-A1298C Compound
Heterozygosity, and Cigarette-Cannabis Smoking: Gene-Environment
Pathophysiological Associations with Buerger’s Disease. Submitted Jan
2005.

Gruppo R, Stroop D, Fontaine RN, Wang P, Glueck CJ. The
polymorphism (K1221Q) of the human glycoprotein PC-1 gene coding
region is strongly associated with race. Circulation, In press, 11/200, to be
presented, National American Heart Association Meeting, New Orleans, LA,
11/14/00

Glueck CJ, Fontaine RN, Wang O. Low molecular weight heparin: a new
treatment for osteonecrosis of the hip. J Invest. Med 2000;48:161.
Presented, Central Society for Clinical Research, Chicago, Illinois, 9/23/00

Gruppo R, Stroop D, Fontaine RN, Wang P, Glueck CJ. The
polymorphism (K121Q of the human glycoprotein PC-1 gene coding region
is strongly associated with race. J Invest Med 2000;48:173. Presented,
Central Society for Clinical Research, Chicago, Illinois, 9/23/00

Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L. Metformin-
induced resumption of normal ovulatory menses in 11 of 12 (92%)
previously oligo-amenorrheic teenage females with polycystic ovary
syndrome (PCOS). J Invest Med 2000;48:25, Presented, Central Society
for Clinical Research, Chicago, Illinois, 9/23/00

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. The effects of
exogenous estrogen on atherothrombotic vascular disease relates to the
presence or absence of the 20210 G/A prothrombin gene mutation: A cross-
sectional study of 230 hyperlipidemic women. J Invest Med 2000;48:84.
Presented, Central Society for Clinical Research, Chicago, Illinois, 9/23/00

Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis
and thrombophilia in 36 patients referred for low molecular weight heparin
therapy for osteonecrosis. J. Invest. Med. 2000;48:163. Presented, Central
Society for Clinical Research, Chicago, Illinois, 9/23/00

Glueck CJ, Szczybutowicz P, Wang P, Fontaine RN. Three generation
familial osteonecrosis: familial thrombophilia, and hypofibrinolysis. J.
Invest. Med. 2000;48:189A. Presented, Biology 2000, National Meeting of
the AFMR, San Diego, 4/16-18, San Diego, California

Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang J. The
thrombotic Factor V Leiden mutation (resistance to activated protein C) and
estrogen replacement therapy as risk factors for atherothrombotic
cardiovascular disease in 423 hyperlipidemic women. Circulation 1999;110
(suppl 18), 331. Presented, National American Heart Association Meetings,
Atlanta, November, 1999

Glueck CJ, Fontaine RN, Wang P. Interaction of estrogen-mediated and
heritable thrombophilias: pathoetiologies for ischemic optic neuropathy and
ischemic stroke. J Invest. Med. 2000;48:189A. Presented, Biology 2000,
National Meeting of the AFMR, San Diego, 4/16-18, San Diego, California

Phillips H, Glueck CJ, Wang P, Fontaine R, Sieve-Smith L, Tracy T.
Hypofibrinolytic 4G/4G polymorphism of the PAI-1 gene: an independent
pathoetiology of disorders of pregnancy. J Invest Med 1999;47:223A.
Presented, CSCR, Chicago, September 1999.

Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. The
thrombophilic Factor V Leiden mutation (Resistance to Activated Protein C)
is not a significant risk factor for atherothrombotic vascular disease in 396
hyperlipidemic men. J Invest Med 1999;47:246A Presented, CSCR,
Chicago, September 1999.

Glueck CJ, Wang P, Fontaine R, Sieve-Smith L. Tracy T. Plasminogen
activator inhibitory activity: an independent cause of the high miscarriage
rate during pregnancy in women with polycystic ovary syndrome. J Invest
Med1999;47:220A Presented, CSCR, Chicago, September 1999.

Phillips H, Glueck CJ, Wang P, Fontaine R, Sieve-Smith L, Tracy T. Four
gene mutations producing heritable thrombophilia and hypofibrinolysis:
Pathoetiologies of pregnancy complications. J Invest Med 1999;47:246A,
1999 Presented, CSCR, Chicago, September 1999.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T.
Hypofibrinolysis may cause the high miscarriage rate during pregnancy in
women with polycystic ovary syndrome. FASEB Journal 1999;13:LB144
(Abstract) Presented, AFCR/FASEB National Meetings, Washington DC,
4/17-21/99

Glueck, C.J., T. Tracy. P. Wang, L. Sieve-Smith, R.N. Fontaine and A.
Gupta. Metformin, coronary heart disease risk factors, and resumption of
normal menses in amenorrheic women with polycystic ovary syndrome.
Circulation 1998;98 (suppl 17), 143. Presented, National American Heart
Association Meeting, Dallas, 10/17-19, 1998.

Glueck, C.J. Wang, P., Fontaine, R., Tracy, T., and Sieve-Smith, L. (1999)
Metformin-induced resumption of normal menses in 39 of 43 (91%)
previously amenorrheic women with the polycystic ovary syndrome.
Metabolism, April 1999.

Glueck, C.J., R.N. Fontaine, R.A. Freiberg, R. McMahon, T. Tracy and P.
Wang (1998) The 4G/5G polymorphism in the plasminogen activator gene:
hypofibrinolysis and
atherothrombosis. J. Invest. Med. 289A.

Glueck, C.J., T. Tracy, P. Wang, L. Seive-Smith, and R.N. Fontaine
(1998) Metformin, coronary heart disease risk factors and induces
resumption of normal menses in previously amenorreic women with
polycystic ovary syndrome. J. Invest. Med. 273A. Presented, National
American Heart Association Meeting, Dallas, 10/17-19, 1998.

Glueck, C.J., H. Bell, L. Vadlamani, A. Gupta, R.N. Fontaine, P. Wang, D.
Stroop and R. Gruppo (1998) The mutant factor V Leiden gene, 4G/4G
polymorphism of the plasminogen activator inhibitor gene (PAI-1), high Lp
(a), and PAI:Lp(a) interactions: common heritable thrombophilic and
hypofibrinolytic pathoetiologies of retinal vein occlusion. J. Invest. Med.
254A.

Fontaine, R.N., A. Gupta, P. Wang and C.J. Glueck (1998) Allele- specific
amplification refractory mutation system for genotyping the 4G/5G
polymorphism in the promotor region of the plasminogen activator inhibitor-
1 gene. J. Invest. Med. 231A. Presented, Biomedicine 98, Washington DC,
May2, 1998.

Glueck, C.J. R.A. Freiberg, R. Gruppo, P. Kirk, R.N. Fontaine, A. Gupta,
T. Tracy, and P. Wang (1998) Amelioration of osteonecrosis by treatment
of thrombophilia and hypofibrinolysis. J. Invest. Med. 227A. Presented,
Biomedicine 98, Washington DC, May 2, 1998.

Vadlamani, L. Glueck, C.J. H. Bell., A. Gupta, R.N. Fontaine, P. Wang, T.
Tracy, D. Stroop, and R. Gruppo (1998) Heritable thrombophilia and
hypofibrinolysis: Common pathoetiologies of retinal vein thrombosis. J.
Invest. Med. 214A. Presented, biomedicine 98, Washington DC, May2,
1998

Glueck, C.J., T. Tracy, P. Wang, L. Sieve-Smith, R.N. Fontaine and A.
Gupta (1998) Metformin-induced resumption of normal menses in 19 of 23
(83%) previously amenorrheic women with polycystic ovary syndrome. J.
Invest. Med. 208A. Presented, Biomedicine 98, Washington DC, May 2,
1998.

Glueck, C.J., R.N. Fontaine, A. Gupta, T. Tracy and P. Wang (1997)
Familial 4G/4G homozygosity in the plasminogen-activator inhibitor gene
promotor, hyperinsulinemia, thrombosis, and osteonecrosis. J. Invest. Med.
331A. Presented, Central Society for Clinical Research, Chicago, Sept. 25,
1997.

Glueck, C.J., R.N. Fontaine, A. Gupta, T. Tracy and P. Wang (1997)
4G/4G and 4G/5G polymorphisms in the plasminogen-activator inhibitor
gene promotor: Associations with plasminogen activator inhibitor activity,
insulin, and triglycerides. J. Invest. Med. 330A. Presented, Central Society
for Clinical Research, Chicago, Sept. 25, 1997.

Glueck, C.J., R.N. Fontaine, A. Gupta, T. Tracy, P. Wang (1997) A major
gene for plasminogen activator inhibitor activity. J. Invest. Med. 45:314A.
Presented, Central Society for Clinical Research, Chicago, Sept. 25, 1997.

Fontaine, R.N., Gupta, A., Glueck, C.J. 4G/4G homozygosity in the
plasminogen activator inhibitor gene promotor in patients with familial high
plasminogen-activator inhibitor. J of Investigational Medicine 45(3):261A
Presented, Biomedicine 97’,Washington DC, April 26-27, 1997.
Outstanding Abstract Award, Biomedicine 1997

Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P Weksler BB, Eldor A.
The hypofibrinolytic 4G/4G polymorphism of the plasminogen activator
inhibitor-1 (PAI-1) gene in women with obstetric complications. J Invest
Med 2000;48:1622. Presented, Central Society for Clinical Research,
Chicago, Illinois, 9/23/00